SS Innovations Announces Completion of an $18.6 Million Private Placement to Support Growth Initiatives

Rhea-AI Summary

SS Innovations (NASDAQ: SSII) completed a private placement on March 6, 2026, raising approximately $18.6 million in gross proceeds through the sale of 5,774,839 common shares.

The offering included insider purchases by the CEO, vice-chairman and a director, a $2.5 million investor that triggered a 7% cash commission and five-year warrants, and participation led by Manipal Global Health Services. Proceeds will fund working capital and global expansion, including planned U.S. FDA 510(k) review and EU CE marking efforts for the SSi Mantra surgical robotic system.

Positive

• Gross proceeds of $18.6 million raised in private placement
• Insiders purchased 1,300,006 shares, signaling management confidence
• Lead participation from Manipal Global Health Services supports continuity
• Proceeds earmarked for working capital and global expansion efforts

Negative

• Total issuance of 5,774,839 shares dilutes existing shareholders
• Transaction includes a 7% cash commission and 41,667-share warrants

News Market Reaction – SSII

+5.41%

5 alerts

+5.41% Session close to close

+5.8% Peak Tracked

-5.6% Trough Tracked

$956.23M Market Cap

0.4x Rel. Volume

In the Mar 9 session, SSII gained 5.41%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -5.6% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.4% in the session following this news. A strong positive reaction aligns with SS ...

Analysis

The stock moved +5.4% in the session following this news. A strong positive reaction aligns with SS Innovations’ recent pattern of investor enthusiasm for growth milestones, as seen after revenue and product updates with moves up to 10.84%. The $18.6 million capital raise adds funding for expansion and regulatory efforts. Investors should still weigh dilution from 5,774,839 new shares and additional warrants, and monitor execution against the mid‑2026 FDA 510(k) and 2026 EU CE timelines.

Key Figures

Private placement proceeds: $18.6 million gross Shares issued: 5,774,839 shares Insider tranche: 1,300,006 shares at $4.00 +5 more

8 metrics

Private placement proceeds $18.6 million gross Common stock private placement completed March 6, 2026

Shares issued 5,774,839 shares Total common stock sold in the private placement

Insider tranche 1,300,006 shares at $4.00 Purchased by CEO, Vice-Chairman and a director

Investor tranche 4,474,833 shares at $3.00 Sold to existing and new investors led by Manipal Global Health

Lead investment $2.5 million Investment by one non-affiliate investor triggering fees and warrants

Placement commission $175,000 (7%) Cash commission to FINRA member firm on $2.5M investment

Warrants issued 41,667 warrants at $3.45 Five-year warrants to FINRA member firm

FDA review timeline Mid-2026 Anticipated completion of FDA review of 510(k) for SSi Mantra

Historical Context

5 past events · Latest: Jan 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 13	Preliminary results	Positive	+10.8%	Strong Q4 and full-year 2025 revenue and SSi Mantra installation growth.
Jan 08	Management change	Positive	-1.4%	Appointment of new Global COO and CFO to support growth and scaling.
Jan 06	Product expansion	Positive	+6.5%	Launch of five new 5-mm instruments to broaden robotic surgery use.
Dec 08	Regulatory filing	Positive	+0.6%	Submission of 510(k) for SSi Mantra and update on installed base metrics.
Nov 06	Telesurgery milestone	Positive	-2.3%	First telesurgery using Tele Surgeon Console over a 185-mile distance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent operational and growth updates have mostly led to positive price reactions, though some favorable news has still seen short-term pullbacks.

Recent Company History

Over the last several months, SS Innovations has reported strong growth and product progress. Preliminary Q4 and full-year 2025 revenue showed sharp increases, with an installed base of 168 systems and notable unit growth, prompting a 10.84% gain. Earlier, new 5-mm instruments and procedural milestones, including telesurgery, supported technology adoption. Regulatory steps advanced with a 510(k) submission and expectations for FDA and EU decisions in H1 2026. Leadership changes added execution focus. Against this backdrop, the current private placement adds capital to fund these initiatives.

Key Terms

private placement, FINRA, warrants, exercise price, +3 more

7 terms

private placement financial

"the Company completed a private placement of its common stock (the “Private Placement”)"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

FINRA regulatory

"SS Innovations will pay a FINRA member firm a cash commission of $175,000"

FINRA is the U.S. self‑regulatory organization that oversees brokerage firms and individual brokers, setting and enforcing rules to protect investors and keep markets orderly. Think of it as a referee and rulebook keeper for the broker industry: it licenses brokers, monitors their behavior, enforces standards, and runs complaint and arbitration systems, so investors can check records and have a path to resolve disputes.

View in glossary

warrants financial

"issue to such firm five-year warrants to purchase 41,667 shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

exercise price financial

"warrants to purchase 41,667 shares of our common stock at an exercise price of $3.45"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

u.s. food and drug administration regulatory

"We anticipate that the U.S. Food and Drug Administration will complete its review"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

510(k) premarket notification regulatory

"review of our 510(k) premarket notification for our SSi Mantra surgical robotic system"

A 510(k) premarket notification is a regulatory submission to the U.S. Food and Drug Administration that shows a new medical device is as safe and effective as an existing, legally marketed device. Think of it like demonstrating your new model performs like a trusted older model so it can be sold; for investors, 510(k) clearance is a key hurdle that affects how quickly a device can reach market, development cost, and the level of regulatory risk in a medical-device investment.

ce marking regulatory

"pathway towards a European Union CE marking certification for the SSi Mantra"

CE marking is a symbol placed on certain products showing they meet European Union safety, health and environmental rules required to sell them in the EU/EEA. For investors, it signals that a product has cleared a common regulatory hurdle—like a passport for market access—reducing legal and market-entry risk and often widening sales opportunities across European markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Financing led by Certain of the Company’s Directors and Executive Officers

FORT LAUDERDALE, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that on March 6, 2026, the Company completed a private placement of its common stock (the “Private Placement”) which generated approximately $18.6 million in gross proceeds, before deducting offering expenses.

In the offering, the Company offered and sold a total of 5,774,839 shares of common stock consisting of:

• an aggregate of 1,300,006 shares of common stock at an average price of $4.00 per share, or a total of approximately $5.2 million, to Dr. Sudhir Srivastava, our Chairman and Chief Executive Officer ($2.0 million), Dr. Frederic H. Moll, our Vice-Chairman ($2.0 million), and Tim Adams, a director ($1.197 million); and
  
• an aggregate of 4,474,833 shares of common stock at $3.00 per share, or a total of approximately $13.4 million, to existing and new investors, led by Manipal Global Health Services, an existing shareholder.  
  

SS Innovations intends to use the net proceeds from this financing for working capital and other general corporate purposes, including advancing the Company’s global expansion efforts.

In connection with a $2.5 million investment by one of the non-affiliate investors in the Private Placement, SS Innovations will pay a FINRA member firm a cash commission of $175,000 (7% of the investment) and issue to such firm five-year warrants to purchase 41,667 shares of our common stock at an exercise price of $3.45 per share.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “The net proceeds from this financing will advance our growth initiatives in India and other existing global markets, while supporting our preparation for entry into the United States and European Union markets. We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for our SSi Mantra surgical robotic system by mid-2026. We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can also obtain in 2026.”

Dr. Srivastava continued, “Insider participation in this financing reflects our strong confidence in SS Innovations’ future and our commitment to democratizing access to world-class surgical robotic care. We appreciate the continuing support of Manipal Global Health Services, a large existing shareholder, and welcome a respected group of new shareholders in the Company.”

The securities being sold in the Private Placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws and accordingly may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of robotic surgical procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.

Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we do not assume any obligation to update any forward-looking statement.

Investor Contact:
The Equity Group        
Kalle Ahl, CFA                
T: (303) 953-9878        
kahl@theequitygroup.com

Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@theequitygroup.com

Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com

FAQ

How much did SS Innovations (SSII) raise in the March 6, 2026 private placement?

SS Innovations raised approximately $18.6 million in gross proceeds. According to the company, the offering sold 5,774,839 common shares to insiders, existing shareholders and new investors to support growth initiatives.

Who participated in SS Innovations' (SSII) private placement and what insider purchases occurred?

Insiders bought an aggregate of 1,300,006 shares, including the CEO and vice-chairman. According to the company, insider participation totaled about $5.2 million, reflecting management's support for the financing.

What will SS Innovations (SSII) use the net proceeds from the $18.6M private placement for?

The company will use net proceeds for working capital and global expansion. According to the company, funds will advance efforts in India and support preparation for U.S. FDA and EU CE market entry for the SSi Mantra system.

Did the private placement include any commissions or warrants that affect SS Innovations (SSII) shareholders?

Yes; a non-affiliate investor’s $2.5M triggered a 7% cash commission and issuance of five-year warrants for 41,667 shares. According to the company, this results in additional compensation-related dilution and expense.

How many shares were sold at each price tier in SS Innovations' (SSII) financing?

The offering sold 1,300,006 shares at an average $4.00 and 4,474,833 shares at $3.00. According to the company, the two-tier sale generated approximately $5.2 million and $13.4 million respectively.